68Ga-DOTATATE PET for Management of Neuroendocrine Tumours

Titre officiel

The Clinical Impact of 68Ga-DOTATATE PET in the Management of Patients With Neuroendocrine Tumours

Sommaire:

Il s’agit d’une étude visant à recueillir de l’information sur l’utilité de la tomographie par émission de positons (TEP) à l’aide d’un colorant spécial appelé 68Ga-DOTATATE pour les patients atteints de tumeurs neuroendocrines en déterminant le nombre de patients dont la prise en charge clinique a été modifiée à la suite de cet examen.

Description de l'essai

Primary Outcome:

  • Number of participants for whom the intended clinical management prior to PET is changed after 68Ga-DOTATATE PET.
When patients are suspected of having neuroendocrine tumours, they will usually undergo various imaging scans such as computed tomography (CT) scan and magnetic resonance imaging (MRI), and octreotide scintigraphy (octreoscan) to try to identify the primary tumour. During the patients' course of disease, they will continue to have various CT, MRI, and/or octreoscans. Sometimes, despite using scans, laboratory tests, and examination, it is still difficult to properly diagnose neuroendocrine tumours. Doctors have found that most neuroendocrine tumours make too much of a hormone called somatostatin on their cell surface. Because of this doctors have been using positron emission tomography (PET) scans using a special contrast dye called 68Ga-DOTATATE in hopes of better diagnosing and managing neuroendocrine tumours. 68Ga-DOTATATE can label the cells that have somatostatin (such as neuroendocrine tumour cells) so that the PET scan can take better pictures and doctors can better diagnose and manage the disease. However, despite 68Ga-DOTATATE PET scans showing promise, it is still not widely accessible. Because of this, researchers are creating a registry for patients who may need 68Ga-DOTATATE PET scans to:
  • Identify their primary tumour where the doctor suspects is a neuroendocrine tumour
  • Staging of the neuroendocrine tumour
  • Restage the tumour prior to surgery/radiotherapy or help to assess the tumour where standard scans such as CTs, MRIs, or octreoscans are not properly showing your tumours despite other clinical or laboratory tests showing that your disease has progressed
  • For other issues when confirmation of site of disease and/or disease extent may impact clinical management of the neuroendocrine tumour. This registry help the participant's treating physician to obtain approval for the participant to undergo 68Ga-DOTATATE PET scans for their neuroendocrine tumour.

Voir cet essai sur ClinicalTrials.gov

Intéressé(e) par cet essai?

Imprimez cette page et apportez-la chez votre médecin pour discuter de votre admissibilité à cet essai et des options de traitement. Seul votre médecin peut vous recommander pour un essai clinique.

Ressources

Société canadienne du cancer

Ces ressources sont fournies en partenariat avec Société canadienne du cancer